A
AstraZeneca PLC (AZN)
NYQ – Real vaqt narxi. Valyuta: USD
188.41
+2.73 (1.47%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
188.01
-0.40 (-0.21%)
Bozordan keyin: Jun 26, 2026, 7:39 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
188.41
+2.73 (1.47%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
188.01
-0.40 (-0.21%)
Bozordan keyin: Jun 26, 2026, 7:39 PM EDT
AstraZeneca PLC, biopharmatsiya kompaniyasi, retsept bo'yicha dorilarni kashf qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirishga qaratilgan. Kompaniya Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules va Symbicort pMDI ni taklif etadi. Shuningdek, u Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium va boshqa dorilarni taqdim etadi. Kompaniya o'z mahsulotlarini onkologiya, yurak-qon tomir, buyrak va metabolizm, nafas olish va immunologiya, vaktsinalar va immunitet, hamda kam uchraydigan kasalliklar terapiyasi uchun taklif etadi. U Buyuk Britaniya, Amerika, Yevropaning qolgan qismi, Osiyo, Afrika va Australaziyadagi distribyutorlar va mahalliy vakolatxonalar orqali birlamchi va ixtisoslashtirilgan shifokorlarga xizmat ko'rsatadi. U onkologiyada eng katta multimodal fond modelini ishlab chiqish bo'yicha Tempus va Pathos bilan, bir nechta ko'rsatkichlar bo'yicha kasalliklarni davolash potentsialiga ega yangi og'iz orqali qabul qilinadigan nomzodlarni kashf qilish va rivojlantirish bo'yicha CSPC Pharmaceutical Group Limited bilan, hamda radioterapiya kon'yugatlarining terapevtik javobini bashorat qilishni ishlab chiqish bo'yicha Nucs AI Inc. bilan strategik kelishuvlarga ega. Kompaniya ilgari Zeneca Group PLC nomi bilan tanilgan va 1999 yil aprel oyida AstraZeneca PLC nomini o'zgartirgan. AstraZeneca PLC 1992 yilda tashkil etilgan va uning shtab-kvartirasi Buyuk Britaniyaning Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Aradhana Sarin M.D. | CFO & Executive Director |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology R&D |
| Mr. David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit |
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
| Mr. Joris Silon | Head of Investor Relations |
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | CEO & Executive Director |
| Ms. Iskra Reic | Executive Vice President of International |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| Ms. Ruth March FMEDSCI, O.B.E., Ph.D. | Senior VP of Precision Medicine - R&D Oncology |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-15 | 6-K | a1987i.htm |
| 2026-06-01 | 6-K | a4701g.htm |
| 2026-05-29 | 6-K | a1377g.htm |
| 2026-05-27 | 6-K | a7798f.htm |
| 2026-05-26 | 6-K | a6568f.htm |
| 2026-05-18 | 6-K | a6159e.htm |
| 2026-05-14 | 6-K | a3223e.htm |
| 2026-05-01 | 6-K | a7026c.htm |
| 2026-04-29 | 6-K | a2999c.htm |
| 2026-04-28 | 6-K | a1866c.htm |